Vineet Laboratories Limited
The Board of Directors of Vineet Laboratories Limited at its meeting held today i.e., on Thursday, November 27, 2025, approved the following:1. Raise of funds by way of issue of equity shares of the Company of face value Rs.10/- (RupeeTen Only) each for an aggregate amount not exceeding Rs.3,000 Lakhs (Rupees ThreeThousand Lakhs) on Right issue basis, on such terms and conditions as may be decided bythe Board of Directors / Rights Issue Committee to the eligible equity shareholders of theCompany, as on the record date (to be notified subsequently).The issue is subject to the receipt of applicable regulatory, statutory approvals, inaccordance with the provisions of the Securities and Exchange Board of India (Issue ofCapital and Disclosure Requirements) Regulations, 2018, Securities and Exchange Board ofIndia (Listing Obligations and Disclosure Requirements), Regulations, 2015, and theCompanies Act, 2013 and the rules made thereunder, as amended from time to time.2. Constitution of the Rights Issue Committee, consisting of Mr. Gaddam Venkata Ramana,Mr. Satyanarayana Raju Bhupathiraju, Mr. Premananda Reddy Vennapusa, Mr. Dilip VishnuAcharekar empowering them to undertake all the necessary activities for the completion ofthe proposed Rights Issue. |SUBJECT: Rights Issue
More Stories
Bhagiradha Chemicals & Industries Limited
Bhagiradha Chemicals & Industries Limited has informed the Exchange regarding 'Intimation under Regulation 30 of the SEBI (Listing Obligations and...
HFCL Limited
HFCL Limited has informed the Exchange about Sale of HFCL Limited s Thermal Weapon Sights ( TWS ) business to...
Oil & Natural Gas Corporation Limited
Oil & Natural Gas Corporation Limited has informed the Exchange about Corrigendum in respect of Announcement Appointment of Director (Finance)...
HFCL Limited
HFCL Limited has informed the Exchange about Sale of up to 80% of the paid-up share capital of Raddef Private...
Amit Spinning Industries Limited
Amit Spinning Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. |SUBJECT:...
Akums Drugs and Pharmaceuticals Limited
Intimation of Schedule of the Investor/Analysts Meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

Average Rating